{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:07Z","timestamp":1790745307410,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006847","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000}}],"reference-count":151,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006847.pub2","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T22:44:07Z","timestamp":1516056247000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Gefitinib for advanced non-small cell lung cancer"],"prefix":"10.1002","volume":"2018","author":[{"given":"Esther HA","family":"Sim","sequence":"first","affiliation":[{"name":"GenesisCare Radiation Oncology; 1 Medical Place Urraween Queensland Australia 4655"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A","family":"Yang","sequence":"additional","affiliation":[{"name":"The University of Queensland; UQ Thoracic Research Centre, School of Medicine; Brisbane Australia"},{"name":"The Prince Charles Hospital; Department of Thoracic Medicine; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wood-Baker","sequence":"additional","affiliation":[{"name":"University of Tasmania; School of Medicine; Hobart Tasmania Australia 7001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayleen V","family":"Bowman","sequence":"additional","affiliation":[{"name":"The Prince Charles Hospital; Department of Thoracic Medicine; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwun M","family":"Fong","sequence":"additional","affiliation":[{"name":"The Prince Charles Hospital; Department of Thoracic Medicine; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"10.1002\/14651858.CD006847.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.lungcan.2012.03.011","article-title":"Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer","volume":"77","author":"Ahn","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12253-016-0067-4","article-title":"Study of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring EGFR mutation","volume":"22","author":"An","year":"2016","journal-title":"Pathology and Oncology Research"},{"issue":"9","key":"10.1002\/14651858.CD006847.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cncr.22616","article-title":"Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy","volume":"109","author":"Chen","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/JTO.0b013e3182121c09","article-title":"A phase II randomized trial of gefitinib alone or with Tegafur\/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy","volume":"6","author":"Chen","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"20","key":"10.1002\/14651858.CD006847.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","article-title":"Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations","volume":"27","author":"Cheng","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD006847.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2007.15.0672","article-title":"Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study","volume":"26","author":"Crino","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.cad.0000203381.99490.ab","article-title":"Phase II, open-label, randomized study (SIGN) or single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer","volume":"17","author":"Cufer","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0008|cit8","first-page":"405","article-title":"A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer","volume":"16","author":"Dai","year":"2013","journal-title":"Chinese Journal of Lung Cancer"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006847.pub2-BIB0009|cit9","first-page":"131 Abs 481","article-title":"Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non-small cell lung cancer (NSCLC) patient","volume":"13","author":"Baelga","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0010|cit10","unstructured":"Douillard JY Giaccone G Horai T Noda K Vansteenkiste JF Takata I Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract] 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA 2002 299a, Abs 1195"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0011|cit11","first-page":"131, Abs 480","article-title":"Improvement in disease-related symptoms and quality of life (QOL) for advanced non-small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2","volume":"13 Suppl 5","author":"Douillard","year":"2002","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD006847.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0013|cit13","unstructured":"Fukuoka M Yano S Giaccone G 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA 2002 298a, Abs 1188"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0014|cit14","first-page":"S45","article-title":"Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd\/3rd-line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1)","volume":"128 Suppl 1","author":"Manegold","year":"2002","journal-title":"Journal of Cancer Research & Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0015|cit15","first-page":"567","article-title":"Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib","volume":"31","author":"Nishiwaki","year":"2004","journal-title":"Gan to Kagaku Ryoho. Cancer & Chemotherapy"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0016|cit16","unstructured":"Vansteenkiste J Natale R Giaccone G Two randomised, double-blind studies of ZD1839 in 425 patients with pretreated advanced non-small-call lung cancer (IDEAL 1 and IDEAL 2) [abstract] European Respiratory Society Annual Congress Stockholm 2002 Abstract 2537"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Gaafar R M Surmont V Scagliotti G Van Klaveren R Papamichael D Welch J A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01\/03) 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States American Society of Clinical Oncology 2010","DOI":"10.1200\/jco.2010.28.15_suppl.7518"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.ejca.2011.06.045","article-title":"A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021\/ILCP 01\/03)","volume":"47","author":"Gaafar","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Surmont VF Gaafar RM Scagliotti GV Van Klaveren RJ Papamichael D Hasan B A double-blind, randomized, placebo-controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first-line platinum-based chemotherapy (EORTC 08021- ILCP) 35th ESMO Congress Milan Italy Oxford University Press 2010 viii124","DOI":"10.1200\/jco.2010.28.15_suppl.7518"},{"issue":"31","key":"10.1002\/14651858.CD006847.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial - INTACT I","volume":"22","author":"Giaccone","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0022|cit22","first-page":"2, Abstract 4","article-title":"A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1)","volume":"13 Suppl 5","author":"Giaccone","year":"2002","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.1002\/14651858.CD006847.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2008.18.4408","article-title":"Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status","volume":"27","author":"Goss","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD006847.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1002\/cncr.25863","article-title":"DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma","volume":"117","author":"Han","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0027|cit27","first-page":"127, Abstract 4","article-title":"ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2)","volume":"13 Suppl 5","author":"Johnson","year":"2002","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD006847.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Kelly K Gaspar LE Chansky K Albain KS Crowley J Gandara DR Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa\/placebo maintenance in patients with inoperable stage III non-small cell lung cancer [abstract] 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13-17 May, 2005 (Abstract No. 7058) 2005 634","DOI":"10.1016\/S0169-5002(05)80277-6"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","article-title":"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: from the randomized phase III INTEREST Trial","volume":"28","author":"Douillard","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Horgan AM Bradbury PA Amir E Ng R Douillard JY Kim ES An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-\/third-line therapy in advanced non-small-cell lung cancer Annals of Oncology 2011 1805 11","DOI":"10.1093\/annonc\/mdq682"},{"issue":"15 Suppl Pt 1","key":"10.1002\/14651858.CD006847.pub2-BIB0032|cit32","first-page":"451","article-title":"Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer [abstract no. 8110]","volume":"25","author":"Horgan","year":"2008","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006847.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4143\/crt.2014.307","article-title":"Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non-small cell lung cancer","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Research and Treatment"},{"issue":"13","key":"10.1002\/14651858.CD006847.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0036|cit36","unstructured":"Kris MG Natale RB Herbst RS A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract] 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA 2002 292a Abstract 1166"},{"issue":"16","key":"10.1002\/14651858.CD006847.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0038|cit38","unstructured":"Natale RB Skarin A Maddox AM Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract] 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA 2002 292a, Abstract 1167"},{"issue":"15 Suppl Pt I","key":"10.1002\/14651858.CD006847.pub2-BIB0039|cit39","first-page":"430","article-title":"A randomized open-label study of gefitinib versus docetaxel in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy [abstract no. 8025]","volume":"26","author":"Lee","year":"2008","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-09-1903","article-title":"Randomized phase III trial of gefitinib versus docetaxel in non-small-cell lung cancer patients who have previously received platinum-based chemotherapy","volume":"16","author":"Lee","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0041|cit41","first-page":"16","article-title":"Second-line treatment with gefitinib or docetaxel for advanced non-small cell lung cancer","volume":"37","author":"Li","year":"2010","journal-title":"Chinese Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD006847.pub2-BIB0042|cit42","first-page":"2337","article-title":"Efficacies of gefitinib versus paclitaxel\/carboplatin for patients with advanced pulmonary adenocarcinoma","volume":"94","author":"Lou","year":"2014","journal-title":"National Medical Journal of China"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.02.004","article-title":"Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation","volume":"88","author":"Fukuhara","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Inoue A Kobayashi K Maemondo M Sugawara S Oizumi S Isobe H Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Annals of Oncology 2013 54 9","DOI":"10.1093\/annonc\/mds214"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Inoue A Kobayashi K Maemondo M A randomized phase III study comparing gefitinib with carboplatin\u00a0(CBDCA) plus paclitaxel\u00a0(TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study European Journal of Cancer 2009 Abstract 9LBA","DOI":"10.1016\/S1359-6349(09)72038-5"},{"issue":"25","key":"10.1002\/14651858.CD006847.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006847.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jjco\/hyv054","article-title":"Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)","volume":"45","author":"Miyauchi","year":"2015","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Oizumi S Kobayashi K Inoue A Maemondo M Sugawara S Yoshizawa H Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan study group 002 trial Oncologist 2012 863 70","DOI":"10.1634\/theoncologist.2011-0426"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0049|cit49","unstructured":"Yoshizawa H Kobayashi K Inoue A Maemondo M Sugawara S Oizumi S QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non-small cell lung cancer with mutated EGFR 35th ESMO Congress Milan Italy Oxford University Press 2010 viii122"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0050|cit50","first-page":"109","article-title":"The impact of response evaluation committee in a Phase III study (V-15-32) of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer [Abstract No. 298P]","volume":"19 Suppl 8","author":"Leki","year":"2009","journal-title":"Annals of Oncology"},{"issue":"26","key":"10.1002\/14651858.CD006847.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD006847.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/annonc\/mdp031","article-title":"Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel","volume":"20","author":"Sekine","year":"2009","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006847.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/JTO.0b013e3181da36db","article-title":"Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small-cell lung cancer patients","volume":"5","author":"Yamamoto","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Mitsudomi T Morita S Yatabe Y Negoro S Okamoto I Seto T Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States American Society of Clinical Oncology 2012","DOI":"10.1200\/jco.2012.30.15_suppl.7521"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Tsurutani J Mitsudomi T Mori S Okamoto I Nozaki K Tada H A\u00a0phase III, first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O-9002] European Journal of Cancer 2009 505","DOI":"10.1016\/S1359-6349(09)71715-X"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0058|cit58","first-page":"Viii1","article-title":"Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin\/paclitaxel (C\/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS)","volume":"19 Suppl 8","author":"Mok","year":"2008","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006847.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD006847.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1200\/jco.2009.27.15_suppl.8044","article-title":"Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin\/paclitaxel (C\/P) in selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan","volume":"29","author":"Ohe","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e31822adaf7","article-title":"Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)","volume":"6","author":"Thongprasert","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD006847.pub2-BIB0062|cit62","first-page":"S80","article-title":"Quality of life (QOL) in a randomized phase III first-line study of gefitinib (G) vs carboplatin\/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS)","volume":"5","author":"Thongprasert","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1743-7563.2012.01518.x","article-title":"Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China","volume":"8","author":"Wu","year":"2012","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Wu Y Fukuoka M Mok T S K Saijo N Thongprasert S Yang J C H Tumour response, skin rash and health-related quality of life (HRQOL) - Post-HOC data from the IPASS study European Multidisciplinary Cancer Congress Stockholm Sweden 2011 S633 4","DOI":"10.1016\/S0959-8049(11)72446-7"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Wu Y Mok T Chu D Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin\/paclitaxel (C\/P) (IPASS) Journal of Clinical Oncology 2009 8041","DOI":"10.1200\/jco.2009.27.15_suppl.8041"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2013.03.004","article-title":"Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study","volume":"81","author":"Wu","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0067|cit67","unstructured":"Yang CH Fukuoka M Mok TS Wu YL Thongprasert S Saijo N Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin\/paclitaxel (C\/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS) 35th ESMO Congress Milan Italy Oxford University Press 2010 viii1 2"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Yang J Wu Y L Saijo N Thongprasert S Chu D T Chen Y M Efficacy outcomes in first-line treatment of advanced NSCLC with gefitinib (G) vs carboplatin\/paclitaxel (C\/P) by epidermal growth factor receptor (EGFR) gene-copy number score and by most common EGFR mutation subtypes - Exploratory data from IPASS 2011 European Multidisciplinary Cancer Congress Stockholm Sweden Elsevier Ltd 2011 S633","DOI":"10.1016\/S0959-8049(11)72444-3"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2013.11.021","article-title":"Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)","volume":"83","author":"Yang","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2013.11.021","article-title":"Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)","volume":"83","author":"Yang","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jgo.2015.02.002","article-title":"Similar survival rates with first-line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)","volume":"6","author":"Guetz","year":"2015","journal-title":"Journal of Geriatric Oncology"},{"issue":"15 Suppl Pt I","key":"10.1002\/14651858.CD006847.pub2-BIB0072|cit72","first-page":"445","article-title":"Randomized phase II trial of first-line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small-cell lung cancer (NSCLC) patients (IFCT-0301) [abstract no. 8086]","volume":"26","author":"Morere","year":"2008","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD006847.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.lungcan.2010.03.003","article-title":"Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of\u00a0 2 or 3 (IFCT-0301 study)","volume":"70","author":"Morere","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Ahn M Sun J Ahn JS Kim S Min YJ Yun HJ Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01) ASCO Annual Meeting 2011 Chicago, IL United States American Society of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.7603"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Ahn MJ Sun JM Lee KH Ahn JS Kim SW Min YJ Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01) 14th World Conference on Lung Cancer Amsterdam Netherlands International Association for the Study of Lung Cancer 2011 S317","DOI":"10.1200\/jco.2011.29.15_suppl.7603"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1002\/cncr.27630","article-title":"Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial","volume":"118","author":"Sun","year":"2012","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0078|cit78","first-page":"91","article-title":"Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]","volume":"19 Suppl 8","author":"Okamoto","year":"2008","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.2009.23.3445","article-title":"Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib comparted with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)","volume":"28","author":"Takeda","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD006847.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/01243894-200610000-00014","article-title":"Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study","volume":"1","author":"Chang","year":"2006","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.23282","article-title":"Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced non small-cell lung cancer","volume":"112","author":"Hirsch","year":"2008","journal-title":"Cancer"},{"issue":"31","key":"10.1002\/14651858.CD006847.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"9496","key":"10.1002\/14651858.CD006847.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0084|cit84","first-page":"6242","article-title":"Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non-small cell lung cancer","volume":"8","author":"Xu","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"10648","DOI":"10.1038\/srep10648","article-title":"Randomized, multicenter study of gefitinib dose-escalation in advanced non-small-cell lung cancer patients achieved stable disease after one-month gefitinib treatment","volume":"5","author":"Xue","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0086|cit86","unstructured":"Zhang L Xue C Li N Feng W Jia J Peng J Randomized, open-label, multi-center study of gefitinib dose-escalation (500mg\/d versus 250mg\/d) in advanced NSCLC patient achieved stable disease (SD) after one-month gefitinib treatment 15th World Conference on Lung Cancer Sydney, NSW Australia International Association for the Study of Lung Cancer 2013 S1185"},{"issue":"2","key":"10.1002\/14651858.CD006847.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cllc.2015.12.004","article-title":"First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: quality of life results from a randomized phase III trial","volume":"17","author":"Boye","year":"2016","journal-title":"Clinical Lung Cancer"},{"issue":"2","key":"10.1002\/14651858.CD006847.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4143\/crt.2015.135","article-title":"Tolerability and outcomes of first-line pemetrexed-cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non-squamous non-small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial","volume":"48","author":"Kang","year":"2015","journal-title":"Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.ejca.2014.05.011","article-title":"First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial","volume":"50","author":"Yang","year":"2014","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Yang JC Park K Mok TSK Kang JH Srimuninnimit V Lin CC A randomized phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSQNSCLC) 15th World Conference on Lung Cancer Sydney, NSW Australia International Association for the Study of Lung Cancer 2013 S288","DOI":"10.1016\/j.ejca.2014.03.110"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1200\/jco.2015.33.15_suppl.8041","article-title":"A randomized phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC\/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): final survival results","volume":"15 Suppl","author":"Yang","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006847.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jtho.2015.11.008","article-title":"First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: final overall survival results from a randomized phase 3 study","volume":"11","author":"Yang","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006847.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4161\/cbt.28874","article-title":"A phase II randomized trial evaluating gefitinib intercalated with pemetrexed\/platinum chemotherapy or pemetrexed\/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer","volume":"15","author":"Yu","year":"2014","journal-title":"Cancer Biology and Therapy"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/srep11934","article-title":"QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC","volume":"5","author":"Yang","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1470-2045(12)70117-1","article-title":"Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial","volume":"13","author":"Zhang","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Zhang L Ma SL Song XQ Cheng Y Huang C Yang SJ Pre-planned subgroup analyses from the phase III, randomised, placebo-controlled, parallel-group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non-small-cell lung cancer (NSCLC) (INFORM; C-TONG 0804) European Multidisciplinary Cancer Congress Stockholm Sweden Elsevier Ltd 2011 S622 3","DOI":"10.1016\/S0959-8049(11)72413-3"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Zhang L Ma SL Song XQ Han BH Cheng Y Huang C Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM) (C-TONG 0804) 14th World Conference on Lung Cancer Amsterdam Netherlands International Association for the Study of Lung Cancer 2011 S558 9","DOI":"10.1200\/jco.2011.29.15_suppl.lba7511"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Zhang L Shenglin M Song X Han B Cheng Y Huang C Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804) ASCO Annual Meeting 2011 Chicago, IL United States American Society of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.lba7511"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/JTO.0000000000000445","article-title":"Final overall survival results from a phase III, randomized placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)","volume":"10","author":"Zhao","year":"2015","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12885-015-1714-y","article-title":"Randomized phase II study of paclitaxel\/carboplatin intercalated with gefitinib compared to paclitaxel\/carboplatin alone for chemotherapy-naive non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR","volume":"15","author":"Choi","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2011.05.022","article-title":"Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy","volume":"75","author":"Kim","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0102|cit102","unstructured":"Lee KH Lee KY Jeon YJ A phase IV, multicenter, non-randomized, open-labelled study to evaluate the efficacy of gefitinib (Iressa\u00ae) as a second-line therapy in Korean patients with non-small cell lung cancer (NSCLC) Respirology 2009 A161"},{"issue":"6","key":"10.1002\/14651858.CD006847.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3816\/CLC.2005.n.013","article-title":"A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"6","author":"Manegold","year":"2005","journal-title":"Clinical Lung Cancer"},{"issue":"15","key":"10.1002\/14651858.CD006847.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study","volume":"27","author":"Natale","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Sun Y Shi Y Zhang L Liu X Zhou C Li Z Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States American Society of Clinical Oncology 2012","DOI":"10.1200\/jco.2012.30.15_suppl.7559"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0107|cit107","unstructured":"Sun Y Shi Y Zhang L Liu X Zhou C Wang D A randomized, doubleblind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN) 14th World Conference on Lung Cancer Amsterdam Netherlands International Association for the Study of Lung Cancer 2011 S317 8"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdv063","article-title":"Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005\/TCOG0902","volume":"26","author":"Sugawara","year":"2015","journal-title":"Annals of Oncology"},{"issue":"27","key":"10.1002\/14651858.CD006847.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Yang J Cheng Y Zhao M Zhou Q Yan HH Zhang L A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806) 2013 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States American Society of Clinical Oncology 2013","DOI":"10.1200\/jco.2013.31.15_suppl.8042"},{"issue":"12","key":"10.1002\/14651858.CD006847.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/annonc\/mdu463","article-title":"Pemetrexed versus gefitinib as second-line treatment in advanced non-squamous nonsmall-cell lung cancer patients harbouring wild-type EGFR (CTONG 0806): a multicenter randomized trial","volume":"25","author":"Zhou","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0112|cit112","unstructured":"Zhou Q Cheng Y Zhao MF Yang JJ Yan H H Zhang L Final results of CTONG 0806: a phase II trial comparing pemetrexed with gefitinib as second-line treatment of advanced non-squamous NSCLC patients with wild-type EGFR 15th World Conference on Lung Cancer Sydney, NSW Australia International Association for the Study of Lung Cancer 2013 S194 5"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Bhatnagar AR Singh DP Sharma R Kumbhaj P Docetaxel versus geftinib in patients with locally advanced or metastatic NSCLC pretreated with platinum-based chemotherapy 4th Australian Lung Cancer Conference, ALCC 2012 Adelaide, SA Australia International Association for the Study of Lung Cancer 2012 S159","DOI":"10.1097\/JTO.0b013e318268ff90"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Gaafar RM Surmont V Scagliotti G Van Klaveren R Papamichael G Welch J A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01\/03) Journal of Clinical Oncology 2010","DOI":"10.1200\/jco.2010.28.15_suppl.7518"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Hong J Kyung SY Lee SP Park JW Jung SH Sym SJ Randomized phase II study of pemetrexed versus gefitinib for patients with previously treated non-small cell lung cancer 4th Asia Pacific Lung Cancer Conference, APLCC 2010 Seoul, South Korea International Association for the Study of Lung Cancer 2010 S401","DOI":"10.3904\/kjim.2010.25.3.294"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Laurie SA Miller VA Johnson D Ng KK Heelan RT Pizzo BA Pilot trial of ZD1839 (Iressa-TM-), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer Lung Cancer 2000 S71","DOI":"10.1016\/S0169-5002(00)80230-5"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Lee DH Kim JE Choi YJ Choi CM Lee JS Kim SW Randomized phase II study comparing paclitaxel\/carboplatin intercalated with gefitinib to paclitaxel\/carboplatin alone for chemotherapy-naive non-small cell lung cancer patients either with history of smoking or with wild-type EGFR AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2013 Boston, MA United States American Association for Cancer Research Inc 2013","DOI":"10.1158\/1535-7163.TARG-13-A77"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD006847.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"Abstract 7591","DOI":"10.1200\/jco.2010.28.15_suppl.7591","article-title":"First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n\/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial","volume":"28","author":"Liang","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD006847.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1200\/jco.2006.24.18_suppl.7096","article-title":"A randomized phase II study of sequential carboplatin\/paclitaxel (CP) and gefitinib (G) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Preliminary results","volume":"24","author":"Nokihara","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"15 Suppl Pt I","key":"10.1002\/14651858.CD006847.pub2-BIB0120|cit120","first-page":"441","article-title":"Randomized phase II study of sequential carboplatin\/paclitaxel (CP) and gefitinib (G) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): final results [abstract no. 8069]","volume":"26","author":"Nokihara","year":"2008","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0121|cit121","unstructured":"Puri T Orlando M Barraclough H Enatsu S A randomized phase 2 trial of pemetrexed (P) and gefitinib (G) versus g as first-line treatment for patients with stage IV non-squamous (NS) non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations 15th World Conference on Lung Cancer Sydney, NSW Australia International Association for the Study of Lung Cancer 2013 S1156 7"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0122|cit122","unstructured":"American Cancer Society Cancer facts and figures 2018 Available at: http:\/\/www.cancer.org\/cancer\/lungcancer-non-smallcell\/ (accessed 11th Jan 2018)"},{"issue":"31","key":"10.1002\/14651858.CD006847.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006847.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cllc.2015.12.004","article-title":"First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in east Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: quality of life results from a randomized phase III trial","volume":"17","author":"Boye","year":"2016","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-5002(95)00450-F","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument","volume":"12","author":"Cella","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0895-4356(01)00477-2","article-title":"What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592","volume":"55","author":"Cella","year":"2002","journal-title":"Journal of Clinical Epidemiology"},{"issue":"13","key":"10.1002\/14651858.CD006847.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD006847.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/01243894-200610000-00014","article-title":"Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small-cell lung cancer: Subset analysis from the ISEL study","volume":"1","author":"Chang","year":"2006","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006847.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","article-title":"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: from the randomized phase III INTEREST trial","volume":"28","author":"Douillard","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Fukuoka M Wu YL Thongprasert S Sunpaweravong P Leong SS Sriuranpong V Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) Journal of Clinical Oncology 2011 2866 74","DOI":"10.1200\/JCO.2010.33.4235"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0131|cit131","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"25","key":"10.1002\/14651858.CD006847.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0133|cit133","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"31","key":"10.1002\/14651858.CD006847.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006847.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/1817-1737.65047","article-title":"Frontline gefitinib in advanced non-small cell lung cancer: meta-analysis of published randomized trials","volume":"5","author":"Ibrahim","year":"2010","journal-title":"Annals of Thoracic Medicine"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3109\/0284186X.2010.546368","article-title":"Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials","volume":"50","author":"Jiang","year":"2011","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrclinonc.2011.126","article-title":"Personalized medicine in lung cancer: what we need to know","volume":"8","author":"Mok","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0140|cit140","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program Common terminology criteria for adverse events. Common toxicity criteria, version 4.0 https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 17 February 2017)"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Oizumi S Kobayashi K Inoue A Maemondo M Sugawara S Yoshizawa H Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of north east Japan study group 002 trial Oncologist 2012 863 70","DOI":"10.1634\/theoncologist.2011-0426"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0143|cit143","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0144|cit144","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results drawing conclusions In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD006847.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/annonc\/mdp031","article-title":"Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel","volume":"20","author":"Sekine","year":"2009","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006847.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.clinthera.2005.10.014","article-title":"Erlotinib: small molecule targeted therapy in the treatment of non-small-cell lung cancer","volume":"27","author":"Smith","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006847.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e31822adaf7","article-title":"Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)","volume":"6","author":"Thongprasert","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006847.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/JTO.0b013e3181da36db","article-title":"Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small-cell lung cancer patients","volume":"5","author":"Yamamoto","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006847.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/srep11934","article-title":"QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC","volume":"5","author":"Yang","year":"2015","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1002\/14651858.CD006847.pub2-BIB0151|cit151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006847","article-title":"Gefitinib for advanced non-small cell lung cancer","author":"Sim","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006847.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T17:32:30Z","timestamp":1751218350000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006847.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006847.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732499623.793542180","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]}}}